Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 1
1992 1
1993 2
1996 2
2001 1
2002 5
2003 4
2004 2
2005 4
2006 11
2007 12
2008 17
2009 22
2010 18
2011 10
2012 13
2013 11
2014 12
2015 14
2016 13
2017 22
2018 31
2019 22
2020 30
2021 33
2022 28
Text availability
Article attribute
Article type
Publication date

Search Results

295 results
Results by year
Filters applied: . Clear all
Page 1
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM. Yu KD, et al. Among authors: di gh. JAMA Oncol. 2020 Sep 1;6(9):1390-1396. doi: 10.1001/jamaoncol.2020.2965. JAMA Oncol. 2020. PMID: 32789480 Free PMC article. Clinical Trial.
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.
Lang GT, Jiang YZ, Shi JX, Yang F, Li XG, Pei YC, Zhang CH, Ma D, Xiao Y, Hu PC, Wang H, Yang YS, Guo LW, Lu XX, Xue MZ, Wang P, Cao AY, Ling H, Wang ZH, Yu KD, Di GH, Li DQ, Wang YJ, Yu Y, Shi LM, Hu X, Huang W, Shao ZM. Lang GT, et al. Among authors: di gh. Nat Commun. 2020 Nov 10;11(1):5679. doi: 10.1038/s41467-020-19342-3. Nat Commun. 2020. PMID: 33173047 Free PMC article.
The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation.
Jin X, Xu XE, Jiang YZ, Liu YR, Sun W, Guo YJ, Ren YX, Zuo WJ, Hu X, Huang SL, Shen HJ, Lan F, He YF, Hu GH, Di GH, He XH, Li DQ, Liu S, Yu KD, Shao ZM. Jin X, et al. Among authors: di gh. Sci Adv. 2019 Mar 6;5(3):eaat9820. doi: 10.1126/sciadv.aat9820. eCollection 2019 Mar. Sci Adv. 2019. PMID: 30854423 Free PMC article.
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM. Chen L, et al. Among authors: di gh. Clin Cancer Res. 2022 Jul 1;28(13):2807-2817. doi: 10.1158/1078-0432.CCR-21-4313. Clin Cancer Res. 2022. PMID: 35247906
295 results